Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Cardiology, Columbia University Medical Center, New York, New York.
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901. doi: 10.1016/j.jcin.2016.06.022.
The aim of this study was to investigate the clinical correlates and prognostic impact of coronary artery calcification (CAC) in women undergoing percutaneous coronary intervention with drug-eluting stents (DES).
The clinical correlates and the prognostic significance of CAC in women undergoing percutaneous coronary intervention with DES remain unclear.
Patient-level data from female participants in 26 randomized trials of DES were pooled. Study population was categorized according to the presence of moderate or severe versus mild or no target lesion CAC, assessed through coronary angiography. Co-primary endpoints of interest were the composite of death, myocardial infarction (MI), or target lesion revascularization and death, MI, or stent thrombosis at 3-year follow-up.
Among 11,557 women included in the pooled dataset, CAC status was available in 6,371 women. Of these, 1,622 (25.5%) had moderate or severe CAC. In fully adjusted models, independent correlates of CAC were age, hypertension, hypercholesterolemia, smoking, previous coronary artery bypass graft surgery, and worse left ventricular and renal function. At 3 years, women with CAC were at higher risk for death, MI, or target lesion revascularization (18.2% vs. 13.1%; adjusted hazard ratio: 1.56; 95% confidence interval: 1.33 to 1.84; p < 0.0001) and death, MI, or stent thrombosis (12.7% vs. 8.6%; adjusted hazard ratio: 1.48; 95% confidence interval: 1.21 to 1.80; p = 0.0001). The adverse effect of CAC on ischemic outcomes appeared to be consistent across clinical and angiographic subsets of women, including new-generation DES.
Women undergoing PCI of calcified lesions tend to have worse clinical profile and remain at increased ischemic risk, irrespective of new-generation DES.
本研究旨在探讨女性行经皮冠状动脉介入治疗(PCI)置入药物洗脱支架(DES)后冠状动脉钙化(CAC)的临床相关性及其对预后的影响。
DES 治疗后女性 CAC 的临床相关性及其预后意义尚不清楚。
汇总了 26 项 DES 随机试验中女性患者的个体水平数据。根据冠状动脉造影评估的中等或重度与轻度或无靶病变 CAC,将研究人群分为存在和不存在两种情况。主要终点为 3 年随访时的死亡、心肌梗死(MI)或靶病变血运重建复合终点,以及死亡、MI 或支架血栓形成。
在纳入的汇总数据集的 11557 名女性中,有 6371 名女性的 CAC 状态可用。其中,1622 名(25.5%)有中等或重度 CAC。在完全调整的模型中,CAC 的独立相关因素为年龄、高血压、高胆固醇血症、吸烟、既往冠状动脉旁路移植术和左心室及肾功能较差。3 年时,有 CAC 的女性发生死亡、MI 或靶病变血运重建的风险更高(18.2% vs. 13.1%;调整后的危险比:1.56;95%置信区间:1.33 至 1.84;p<0.0001)和死亡、MI 或支架血栓形成(12.7% vs. 8.6%;调整后的危险比:1.48;95%置信区间:1.21 至 1.80;p=0.0001)。CAC 对缺血性结局的不良影响似乎在女性的各种临床和血管造影亚组中一致,包括新一代 DES。
女性经 PCI 治疗钙化病变的患者往往临床情况更差,缺血风险增加,与新一代 DES 无关。